Although larger-scale validation studies involving more patients are still needed, vinculin and galectin-3 seem to be promising urinary biomarker candidates for recurrent prostate cancer, while secernin-1 seems to be a useful tissue diagnostic biomarker candidate for prostate cancer. Here, LGALS3 is linked to prostate carcinoma.